Navigation Links
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients
Date:1/5/2009

DEERFIELD, Ill. and SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Baxter International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID). The purpose of this clinical trial is to evaluate the safety and efficacy and gain regulatory approval for the treatment of PID using GAMMAGARD LIQUID and rHuPH20 via subcutaneous (under the skin) injection at a single site.

GAMMAGARD LIQUID is currently administered intravenously (IV). Subcutaneous (SC) administration of GAMMAGARD LIQUID with Enhanze Technology is an investigational study and when approved could allow patients to receive a full monthly dose in a single injection site in their home setting.

"Baxter's work with Halozyme represents a commitment to innovation and, in particular, to advancing patient care with GAMMAGARD LIQUID," said Hartmut J. Ehrlich, M.D., vice president of Global Research and Development for Baxter's BioScience business.

"Entering Phase III clinical development is an important achievement for our hyaluronidase enzyme and for our collaboration with Baxter. We are pleased with the progress that has been made since our alliance began in September 2007," stated Jonathan Lim, M.D., President and CEO of Halozyme. "We look forward to continuing our strong working relationship with the Baxter team and to further advance this program."

This Phase III clinical study is a prospective, open-label, non-controlled design that will be conducted in 10-20 centers in the U.S. and Canada. The trial will evaluate the efficacy of GAM
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
2. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
3. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
7. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
8. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
9. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
10. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
11. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Blueprint Medicines (NASDAQ: BPMC ), a ... for genomically defined diseases, today announced that Jeffrey ... overview at the 2015 Wedbush PacGrow Healthcare Conference on ... A live webcast of the event will be ... Medicines website at www.blueprintmedicines.com . An archived replay ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Halozyme ... Quarterly Update Conference Call for the second quarter 2015 ... p.m. PT. Dr. Helen Torley , president and ... same date post-market, Halozyme will release financial results for ... be webcast live through the "Investors" section of Halozyme,s ...
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
(Date:8/3/2015)... , August 3, 2015 According ... on 3D Cell Culture: Asia ... Market Research, the global 3D cell culture market was valued at ... expand at a CAGR of 29.1% to account for ... Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Cornelius, CEO of Bristol-Myers Squibb, MALVERN, ... an,emerging specialty pharmaceutical company focused on improving ... commercialization of treatments,for diseased and aging skin ... President and Chief Executive Officer, will be,presenting ...
... Fla., Oct. 19 An affiliate of,Phlo ... today that,the distribution of its vitality product, ... system-wide coverage within Northern California and has,been ... the,Palm Desert/Palm Springs area. In Northern ...
... BioWa, Inc. (BioWa) announced,today that it ... provides,GlaxoSmithkline (GSK) with access to BioWa,s patented ... cellular,cytotoxicity (ADCC) enhanced antibodies. The agreement ... develop,antibodies based on POTELLIGENT(R) Technology for an ...
Cached Biology Technology:Cutanea to Present at the Paramount BioSciences Healthcare Conference 2AQUISS Continues Expansion Into New Territory 2BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development 2
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... women to participate in the first U.S. study of the safety ... HIV infection. , If it is effective and approved by the ... weapon in the fight against HIV because it would allow women ... to use condoms. , "The significance of the gel is ...
... have visualized in a living animal how cells use a ... create unique and varied proteins. , The scientists say the ... human biology: how the same genes found in every cell ... tissues and organs. These varied proteins, in turn, dictate the ...
... Scientists at the University of Michigan Medical School have ... form of kidney disease and renal failure in children: ... or PLCE1. , Identifying the mutant gene is important ... ?specialized cells that play a vital role in the ...
Cached Biology News:UCSF study will test new vaginal microbicide for herpes and HIV 2UCSF study will test new vaginal microbicide for herpes and HIV 3Living view in animals shows how cells decide to make proteins 2Living view in animals shows how cells decide to make proteins 3Mutant gene causes severe kidney disease in infants 2Mutant gene causes severe kidney disease in infants 3Mutant gene causes severe kidney disease in infants 4
Request Info...
Molecular Biological Resources has extensive abilities cloning and expression of prokaryotic and eukaryotic proteins. Please contact lloconne@molbiores.com to discuss your project. Contact lloconne@...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: